Who are Lyrica (low dose)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gabapentin immediate release, Gabapentin Enacarbil (GEn), Acetaminophen, Gabapentin, Neurontin, Pregabalin and Oxcarbazepine, Imipramine, pregabalin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lyrica-low-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Lyrica (low dose) — Competitive Intelligence Brief

Lyrica (low dose) (Lyrica (low dose)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gabapentinoid; anticonvulsant; analgesic. Area: Neurology; Pain Management.

phase 3 Gabapentinoid; anticonvulsant; analgesic Voltage-gated calcium channel alpha-2-delta subunit Neurology; Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Lyrica (low dose) (Lyrica (low dose)) — KunWha Pharmaceutical Co., Ltd.. Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lyrica (low dose) TARGET	Lyrica (low dose)	KunWha Pharmaceutical Co., Ltd.	phase 3	Gabapentinoid; anticonvulsant; analgesic	Voltage-gated calcium channel alpha-2-delta subunit
Gabapentin immediate release	Gabapentin immediate release	Theresa Zesiewicz, MD	marketed	Anticonvulsant; gabapentinoid	Voltage-gated calcium channel alpha-2-delta subunit
Gabapentin Enacarbil (GEn)	Gabapentin Enacarbil (GEn)	Cleveland Sleep Research Center	marketed	Gabapentinoid; anticonvulsant/neuropathic pain agent	Voltage-gated calcium channel alpha-2-delta subunit
Acetaminophen, Gabapentin	Acetaminophen, Gabapentin	University of Saskatchewan	phase 3	Analgesic combination (non-opioid analgesic + anticonvulsant)	Prostaglandin synthesis (acetaminophen); voltage-gated calcium channel alpha-2-delta subunit (gabapentin)
Neurontin	gabapentin	Generic (originally Parke-Davis/Pfizer)	marketed	Gabapentinoid (anticonvulsant/neuropathic pain agent)	Large neutral amino acids transporter small subunit 1, Adenosine receptor A1, Alpha-2A adrenergic receptor	1993-12-30
Pregabalin and Oxcarbazepine	Pregabalin and Oxcarbazepine	Ju Seok Ryu	marketed	Anticonvulsant combination; Gabapentinoid and aromatic antiepileptic drug	Alpha-2-delta calcium channel subunit (pregabalin); voltage-gated sodium channels (oxcarbazepine)
Imipramine, pregabalin	Imipramine, pregabalin	Odense University Hospital	marketed	Tricyclic antidepressant + gabapentinoid combination	Norepinephrine transporter, serotonin transporter, alpha-2-delta calcium channel subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gabapentinoid; anticonvulsant; analgesic class)

KunWha Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lyrica (low dose) — Competitive Intelligence Brief. https://druglandscape.com/ci/lyrica-low-dose. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab